68 studies found for:    regorafenib
Show Display Options
Rank Status Study
1 Recruiting Regorafenib and Cetuximab in Patients With Advanced Malignancy
Condition: Advanced Cancers
Interventions: Drug: Regorafenib;   Drug: Cetuximab;   Behavioral: Questionnaire
2 Recruiting Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination
Condition: Neoplasms
Interventions: Drug: Regorafenib (Stivarga, BAY73-4506);   Drug: Cetuximab (ERBITUX)
3 Recruiting Single Agent Regorafenib in Refractory Advanced Biliary Cancers
Condition: Cancer of the Bile Duct
Intervention: Drug: Regorafenib
4 Completed Effect of Neomycin on the Pharmacokinetics of Regorafenib
Condition: Neoplasms
Interventions: Drug: Regorafenib (Stivarga, BAY73-4506);   Drug: Neomycin
5 Not yet recruiting [18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib
Condition: Colorectal Cancer
Intervention: Drug: Regorafenib
6 Recruiting Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment
Condition: Neoplasms
Intervention: Drug: Regorafenib (Stivarga, BAY73-4506)
7 Recruiting Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Biological: PF-03446962;   Drug: Regorafenib
8 Recruiting Regorafenib Post-marketing Surveillance
Condition: Colorectal Neoplasms
Intervention: Drug: BAY73-4506_Regorafenib
9 Recruiting Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases
Condition: Colorectal Neoplasms
Interventions: Device: SIR-Spheres;   Drug: Regorafenib
10 Recruiting Regorafenib Post-marketing Surveillance in Japan
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: Regorafenib (Stivarga, BAY73-4506)
11 Recruiting Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer
Condition: Neoplasms
Interventions: Drug: Refametinib (BAY86-9766);   Drug: Regorafenib (Stivarga, BAY73-4506)
12 Recruiting Regorafenib Assessment in Refractory Advanced Colorectal Cancer(RegARd-C)
Condition: Advanced Chemorefractory Colorectal Adenocarcinoma
Intervention: Drug: regorafenib
13 Recruiting Identification of Predictive Biomarker of Regorafenib in Refractory Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Intervention: Drug: Regorafenib
14 Recruiting Regorafenib Versus Placebo to Treat Cholangiocarcinoma
Condition: Cholangiocarcinoma
Interventions: Drug: Regorafenib/active;   Drug: Regorafenib/placebo
15 Recruiting Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers
Condition: Metastatic Colorectal Cancer
Intervention: Drug: Regorafenib
16 Recruiting Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer
Condition: Colorectal Cancer Metastatic
Interventions: Drug: Regorafenib (BAY 73-4506);   Drug: FOLFIRI;   Drug: Placebo
17 Recruiting FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer
Conditions: Esophageal Cancer;   Gastric Cancer
Interventions: Drug: Regorafenib;   Drug: 5-Fluorouracil;   Drug: Leucovorin;   Drug: Oxaliplatin
18 Recruiting Study of Ruxolitinib in Colorectal Cancer Patients
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Ruxolitinib;   Drug: Regorafenib;   Drug: Placebo
19 Recruiting Phase II Study of Regorafenib in Metastatic Soft Tissue Sarcoma
Condition: Sarcoma
Interventions: Drug: Regorafenib;   Drug: Placebo
20 Active, not recruiting Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy
Condition: Colorectal Neoplasms
Intervention: Drug: Regorafenib (BAY73- 4506)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years